People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Other Health Care, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Genomedx Inc. | — | Other Health Care | Series B | $72.9M | $176.3M | 2018 |
| Avila Therapeutics Inc | — | Biotechnology | Series B | $45.0M | $893.0M | 2009 |
| Zikani Therapeutics, Inc. | — | Pharmaceuticals | Series A | $31.7M | $232.3M | 2018 |
| Aeglea BioTherapeutics Holdings, LLC | — | Biotechnology | Series A | $15.8M | $387.1M | 2013 |
Henry Skinner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Henry Skinner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Raj Parekh | 2 | 5 |
| CRAIG JOHNSON | 1 | 16 |
| Amir Nashat | 1 | 14 |
| Bruce Booth | 1 | 12 |
| Michael Liang | 1 | 9 |
| Lawrence Miller | 1 | 8 |
| Daniel Lynch | 1 | 7 |
| Vicki Sato | 1 | 6 |
| Joseph Zakrzewski | 1 | 6 |
| Vikas Goyal | 1 | 5 |
| David Lowe | 1 | 5 |
| Markus Goebel | 1 | 4 |
| Frank Muhlenbeck | 1 | 4 |
| Katrine Bosley | 1 | 4 |
| Andrew Myers | 1 | 4 |
| Mary Szela | 1 | 3 |
| Andrew Levitch | 1 | 3 |
| ROBERT S. EPSTEIN | 1 | 3 |
| Armen Shanafelt | 1 | 3 |
| Tina S. Nova | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.